Ranibizumab for Macular Edema Secondary to RVORanibizumab for Macular Edema Secondary to RVO
A new study compares the efficacy of different doses of ranibizumab for macular edema secondary to RVO -- and whether the addition of non-anti-VEGF treatment provides any additional benefits. BMC Ophthalmology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 29, 2015 Category: Consumer Health News Tags: Ophthalmology Journal Article Source Type: news
Residual Edema With Ranibizumab 0.5 mg and 2.0 mg for DMEResidual Edema With Ranibizumab 0.5 mg and 2.0 mg for DME
How effective is a higher dose of ranibizumab in treating persistent DME? The REEF study investigates. Eye (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 29, 2015 Category: Consumer Health News Tags: Ophthalmology Journal Article Source Type: news
Repeated Intravitreal Ranibizumab May Increase Intraocular PressureRepeated Intravitreal Ranibizumab May Increase Intraocular Pressure
Repeated intravitreal injections of ranibizumab for diabetic macular edema (DME) may result in sustained elevation of intraocular pressure (IOP), according to results from the Diabetic Retinopathy Clinical Research Network investigators. Reuters Health Information (Source: Medscape Ophthalmology Headlines)
Source: Medscape Ophthalmology Headlines - March 5, 2015 Category: Opthalmology Tags: Ophthalmology News Source Type: news
Researcher at Johns Hopkins Helps Lead Discovery on Efficacy and Safety of Eylea, Lucentis and Avastin for Treating Patients with Diabetic Macular Edema - 2/20/15
A researcher from Johns Hopkins Medicine helped lead colleagues from across the country in a government-sponsored study by the Diabetic Retinopathy Clinical Research Network to discover that three drugs — Eylea, Avastin and Lucentis — used to treat diabetic macular edema are all effective. (Source: Johns Hopkins Medicine News)
Source: Johns Hopkins Medicine News - February 20, 2015 Category: Research Source Type: news
Eylea outperforms other drugs for diabetic macular edema with moderate or worse vision loss
Lucentis and Avastin perform similarly to Eylea when vision loss is mild, NIH study shows. (Source: National Institutes of Health (NIH) News Releases)
Source: National Institutes of Health (NIH) News Releases - February 19, 2015 Category: American Health Source Type: news
Johns Hopkins Helps lead discovery on efficacy and safety of 3 drugs for treating DME
(Johns Hopkins Medicine) A researcher from Johns Hopkins Medicine helped lead colleagues from across the country in a government-sponsored study by the Diabetic Retinopathy Clinical Research Network to discover that three drugs -- Eylea, Avastin and Lucentis -- used to treat diabetic macular edema are all effective. They also discovered that Eylea outperformed the other two drugs when vision loss was moderate to severe. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 19, 2015 Category: Global & Universal Source Type: news
Anti-VEGF Drugs Boost Vision in Diabetic Eyes (CME/CE)
(MedPage Today) -- Relative effects of intravitreous aflibercept, bevacizumab, and ranibizumab depend on baseline visual acuity. (Source: MedPage Today Nephrology)
Source: MedPage Today Nephrology - February 19, 2015 Category: Urology & Nephrology Source Type: news
Study Compares Drugs for Diabetes-Linked Eye Disease
Eylea has slight advantage over Avastin, Lucentis for people with macular edema, but cost is an issue (Source: WebMD Health)
Source: WebMD Health - February 19, 2015 Category: Consumer Health News Source Type: news
Anti-VEGF Agents Tied to Improved Visual Acuity in Diabetic Macular Edema (FREE)
By Kelly Young
Edited by Susan Sadoughi, MD
Aflibercept (Eylea), bevacizumab (Avastin), and ranibizumab (Lucentis) all lead to improved vision in patients with diabetic macular edema, although aflibercept may be most effective for those with the worst baseline vision, a New England … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - February 19, 2015 Category: Primary Care Source Type: news
3 Drugs for an Eye Disease, With Big Price Gaps, Are Found to Be Equals for Many
The three drugs — Eylea, Lucentis and Avastin — are meant to treat a condition known as macular edema, which occurs primarily in patients with diabetes. (Source: NYT Health)
Source: NYT Health - February 18, 2015 Category: Consumer Health News Authors: By ANDREW POLLACK Tags: Eyes and Eyesight Roche Holding AG RHHBY Other OTC National Eye Institute Research Eylea (Drug) Regeneron Pharmaceuticals Inc REGN NASDAQ Source Type: news
Study Compares Drugs for Diabetes-Linked Eye Disease
Eylea has slight advantage over Avastin, Lucentis for people with macular edema, but cost is an issue
Source: HealthDay
Related MedlinePlus Pages: Diabetic Eye Problems, Eye Diseases, Retinal Disorders (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - February 18, 2015 Category: Consumer Health News Source Type: news
Ranibizumab reverses vision loss caused by diabetes
(University of Southern California - Health Sciences) Ranibizumab, a prescription drug commonly used to treat age-related vision loss, also reverses vision loss caused by diabetes among Hispanic and non-Hispanic whites, according to a new study led by investigators from the University of Southern California Eye Institute. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 18, 2015 Category: Global & Universal Source Type: news
Eylea outperforms other drugs for diabetic macular edema with moderate or worse vision loss
In an NIH-supported clinical trial comparing three drugs for diabetic macular edema (DME), Eylea (aflibercept) provided greater visual improvement, on average, than did Avastin (bevacizumab) or Lucentis (ranibizumab) when vision was 20/50 or worse at the start of the trial. However, the three drugs resulted in similar average improvement when starting vision was 20/40 to 20/32. Investigators found no major differences in the safety of the three drugs. The trial was funded by the National Eye Institute (NEI), part of the National Institutes of Health.
Language
English (Source: News from NEI)
Source: News from NEI - February 16, 2015 Category: Opthalmology Authors: Jason Source Type: news
BRVO: Bevacizumab and Ranibizumab Both EffectiveBRVO: Bevacizumab and Ranibizumab Both Effective
Treatment with anti-VEGF therapy results in rapid improvements in anatomy and function in patients with macular edema caused by branch retinal vein occlusion. Medscape Medical News (Source: Medscape Ophthalmology Headlines)
Source: Medscape Ophthalmology Headlines - February 11, 2015 Category: Opthalmology Tags: Ophthalmology News Source Type: news
